AbbVie Inc. $ABBV Shares Sold by Parthenon LLC

Parthenon LLC lowered its holdings in AbbVie Inc. (NYSE:ABBV) by 27.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,367 shares of the company’s stock after selling 5,731 shares during the quarter. Parthenon LLC’s holdings in AbbVie were worth $3,558,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Conning Inc. raised its holdings in AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after acquiring an additional 12,690 shares in the last quarter. Diversified Trust Co grew its holdings in AbbVie by 23.6% during the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Dohj LLC increased its position in shares of AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after purchasing an additional 1,335 shares during the last quarter. Permanent Capital Management LP acquired a new stake in shares of AbbVie in the 3rd quarter valued at $720,000. Finally, Railway Pension Investments Ltd lifted its position in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on ABBV. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Morgan Stanley raised their target price on AbbVie from $261.00 to $269.00 and gave the stock an “overweight” rating in a research report on Friday, December 12th. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $219.21 on Monday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The stock has a market capitalization of $387.42 billion, a price-to-earnings ratio of 166.07, a PEG ratio of 0.90 and a beta of 0.36. The company has a 50-day simple moving average of $225.60 and a 200-day simple moving average of $217.60.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter in the previous year, the firm posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.